No Record Found
CALLS | PUTS | |||||||||
Total OI | Chg in Ol | Chg % Ol | LTP | Chg % | Strike Price | Chg % | LTP | Chg % OI | Chg in Ol | Total OI |
No Record Found
sector: Pharmaceuticals
as on 1/25/2021 1:00:21 PM
₹ 5.5 -0.25 -4.35No Record Found
No Record Found
Resolution Type | Desc. of Resolution | Lias Recommendation |
---|
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
Demat Account
Trading Account
PROMOTER - TOTAL37.79%
Indian: 37.06%
Foreign: 0.7271%
NON-PROMOTER - TOTAL 62.21%
Institutions: 8.64%
Non-Institutions: 53.57%
CUSTODIES - 0.00%
Custodies: 0.00%
Y/e 31 Mar( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|
Revenue | 73.16 | 74.90 | 76.83 | 232.14 |
yoy growth (%) | (2.33) | (2.52) | (66.90) | (46.99) |
Raw materials | (63.87) | (92.99) | (329.67) | (256.15) |
As % of sales | 87.30 | 124.14 | 429.07 | 110.34 |
Employee costs | (9.83) | (9.03) | (10.91) | (17.46) |
As % of sales | 13.44 | 12.06 | 14.20 | 7.52 |
Other costs | (16.51) | (19.66) | (43.01) | (37.71) |
As % of sales | 22.57 | 26.25 | 55.97 | 16.25 |
Operating profit | (17.05) | (46.78) | (306.75) | (79.18) |
OPM | (23.31) | (62.45) | (399.24) | (34.11) |
Depreciation | (34.54) | (53.65) | (67.22) | (73.20) |
Interest expense | (8.36) | (10.80) | (107.62) | (98.99) |
Other income | 4.16 | 6.20 | 0.33 | 1.24 |
Profit before tax | (55.79) | (105.03) | (481.27) | (250.13) |
Taxes | (1.76) | (3.05) | (4.43) | (130.32) |
Tax rate | 3.15 | 2.90 | 0.92 | 52.10 |
Minorities and other | -- | -- | -- | -- |
Adj. profit | (57.55) | (108.09) | (485.70) | (380.45) |
Exceptional items | -- | -- | -- | -- |
Net profit | (57.55) | (108.09) | (485.70) | (380.45) |
yoy growth (%) | (46.76) | (77.75) | 27.66 | 184.34 |
NPM | (78.66) | (144.31) | (632.13) | (163.89) |
Y/e 31 Mar ( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|
Equity capital | 87.89 | 87.89 | 87.89 | 87.89 |
Preference capital | -- | -- | -- | -- |
Reserves | (943.24) | (885.69) | (777.60) | (291.90) |
Net worth | (855.35) | (797.80) | (689.71) | (204.01) |
Minority interest | -- | -- | -- | -- |
Debt | 983.03 | 978.38 | 971.40 | 957.29 |
Deferred tax liabilities (net) | 34.70 | 32.94 | 29.89 | 25.46 |
Total liabilities | 162.38 | 213.52 | 311.58 | 778.74 |
Fixed assets | 332.89 | 355.36 | 377.72 | 401.67 |
Intangible assets | -- | -- | -- | -- |
Investments | 0.14 | 0.13 | 0.13 | 0.12 |
Deferred tax asset (net) | 0.92 | 0.92 | 0.92 | 0.92 |
Net working capital | (172.44) | (143.53) | (67.91) | 372.83 |
Inventories | 15.88 | 15.25 | 40.36 | 315.93 |
Inventory Days | 79.23 | 74.31 | 191.73 | 496.74 |
Sundry debtors | 28.82 | 67.12 | 70.23 | 98.24 |
Debtor days | 143.79 | 327.08 | 333.62 | 154.47 |
Other current assets | 30.33 | 45.38 | 79.69 | 123.75 |
Sundry creditors | (81.05) | (105.87) | (93.24) | (102.11) |
Creditor days | 404.38 | 515.91 | 442.93 | 160.55 |
Other current liabilities | (166.42) | (165.41) | (164.95) | (62.98) |
Cash | 0.87 | 0.64 | 0.73 | 3.20 |
Total assets | 162.38 | 213.52 | 311.59 | 778.74 |
Y/e 31 Mar ( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|
Profit before tax | (55.79) | (105.03) | (481.27) | (250.13) |
Depreciation | (34.54) | (53.65) | (67.22) | (73.20) |
Tax paid | (1.76) | (3.05) | (4.43) | (130.32) |
Working capital 27,893 | (666.04) | (610.93) | (558.94) | (77.64) |
Other operating items | -- | -- | -- | -- |
Operating cashflow | (758.13) | (772.67) | (1,111.86) | (531.28) |
Capital expenditure | 295.43 | 262.11 | 101.21 | 87.64 |
Free cash flow | (462.70) | (510.56) | (1,010.65) | (443.64) |
Equity raised | (542.58) | (385.08) | (31.46) | 228.91 |
Investments | (2.39) | 0.11 | 0.06 | 0.05 |
Debt financing/disposal | 676.78 | 594.38 | 263.04 | 176 |
Dividends paid | -- | -- | -- | -- |
Net in cash | (330.89) | (301.15) | (779.01) | (38.69) |
Y/e 31 Mar | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -2.328 | -2.517 | -66.902 | -46.988 |
Op profit growth | -63.545 | -84.751 | 287.401 | -4.424 |
EBIT growth | -49.665 | -74.78 | 147.223 | 9.219 |
Net profit growth | -46.757 | -77.746 | 27.665 | 184.345 |
Profitability ratios (%) | ||||
OPM | -23.31 | -62.453 | -399.235 | -34.109 |
EBIT margin | -64.837 | -125.811 | -486.297 | -65.106 |
Net profit margin | -78.664 | -144.305 | -632.132 | -163.887 |
RoCE | -25.237 | -35.892 | -68.539 | -16.607 |
RoNW | 1.741 | 3.633 | 27.173 | 685.245 |
RoA | -7.655 | -10.292 | -22.273 | -10.451 |
Per share ratios (₹) | ||||
EPS | 0 | 0 | 0 | 0 |
Dividend per share | 0 | 0 | 0 | 0 |
Cash EPS | -14.879 | -26.132 | -89.336 | -73.296 |
Book value per share | -25.237 | -35.892 | -68.539 | -16.607 |
Valuation ratios | ||||
P/E | 0 | 0 | 0 | 0 |
P/CEPS | -0.501 | -0.332 | -0.06 | -0.125 |
P/B | -0.054 | -0.067 | -0.048 | -0.278 |
EV/EBIDTA | -79.748 | -25.416 | -3.277 | -12.969 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 0 |
Tax payout | 3.155 | 2.905 | 0.92 | 52.1 |
Liquidity ratios | ||||
Debtor days | 239.335 | 334.66 | 400.153 | 194.63 |
Inventory days | 77.658 | 135.497 | 846.267 | 537.734 |
Creditor days | -378.15 | -298.635 | -92.942 | -170.844 |
Leverage ratios | ||||
Interest coverage | 5.677 | 8.725 | 3.472 | 1.527 |
Net debt / equity | -1.148 | -1.226 | -1.407 | -4.677 |
Net debt / op. profit | -57.595 | -20.902 | -3.164 | -12.049 |
Cost breakup (₹) | ||||
Material costs | -87.301 | -124.145 | -429.066 | -110.343 |
Employee costs | -13.441 | -12.06 | -14.198 | -7.52 |
Other costs | -22.568 | -26.248 | -55.971 | -16.246 |
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 1,506.25 | 87.73 | 3,61,399.83 | 721.31 | 0.76 | 4,903.66 | 100.23 |
Cipla Ltd | 1,339.45 | 29.12 | 1,08,146.52 | 1,114.14 | 0.63 | 3,798.31 | 346.47 |
Divis Laboratories Ltd | 3,791.95 | 73.80 | 1,00,664.36 | 358.00 | 0.79 | 1,808.00 | 474.52 |
Zydus Lifesciences Ltd | 983.05 | 36.80 | 98,917.83 | 450.40 | 0.61 | 2,225.10 | 145.11 |
Dr Reddys Laboratories Ltd | 5,916.80 | 22.73 | 98,703.03 | 1,034.80 | 0.68 | 5,081.80 | 1,453.13 |
Parabolic Drugs Ltd is one of the fast growing API (Active Pharmaceutical Ingredients) and API intermediate manufacturing and marketing company. The company is in SME segment, with increasing international presence and a strong R&D foundation. The company is based in Chandigarh. They have one subsidiary company namely Parabolic Research Labs Ltd.The company produces the SSP and Cephalosporin range of antibiotics in oral and sterile form, along with their intermediates. They supply APIs to a number of domestic and international companies. The company has two manufacturing facilities at Derabassi, Punjab, and Panchkula, Haryana. They have an established R&D setup which comprises chemical and analytical research laboratories at their facility at Sundhran, Derabassi.Parabolic Drugs Ltd was incorporated in the year 1996. In the year 1998, the company commenced commercial production of oral Semi Synthetic Penicillin APIs by setting up a unit at Derabassi. In the year 1999, they made a contract manufacturing agreement with DSM Laboratories. In 2001, the company undertook a backward integration programme to start production of penicillin intermediates. They made an agreement with Ranbaxy Laboratories for manufacturing SSPs Oral API. In the year 2003, the company entered into export market through direct and third party exports. They launched Flucloxacillin Sodium and Dicloxacillin Sodium in export markets. In the year 2004, they set their regulatory affairs department for the... Read More
Reports by Parabolic Drugs Ltd
Reports by Parabolic Drugs Ltd
No Record Found
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.